Clinical validation of T1ρ mapping for the assessment of hepatic fibrosis in patients with chronic liver disease - Takeaways - MDSpire

Clinical validation of T1ρ mapping for the assessment of hepatic fibrosis in patients with chronic liver disease

  • By

  • Narine Mesropyan

  • Johannes Chang

  • Philipp Lutz

  • Felix Kaiser

  • Oliver M. Weber

  • Christoph Katemann

  • Tatjana Dell

  • Dmitrij Kravchenko

  • Can Yueksel

  • Daniel Kuetting

  • Claus C. Pieper

  • Julian A. Luetkens

  • Alexander Isaak

  • December 20, 2025

  • 0 min

Share

  • 1

    Hepatic fibrosis is a key prognostic factor in liver disease, with risk increasing at each fibrosis stage.

  • 2

    T1ρ mapping is a promising non-invasive technique for assessing hepatic fibrosis, potentially outperforming conventional methods.

  • 3

    The study aims to validate T1ρ mapping's diagnostic utility across the spectrum of chronic liver disease, including steatotic liver disease.

  • 4

    MRI examinations included T1, T2, ECV, and T1ρ mapping, with MRE-based liver stiffness as the reference standard.

  • 5

    Image analysis was performed by an experienced radiologist, ensuring accurate assessment of liver parenchyma using quantitative maps.

Original Source(s)

Clinical validation of T1ρ mapping for the assessment of hepatic fibrosis in patients with chronic liver disease

  • by Narine Mesropyan, Johannes Chang, Philipp Lutz, Felix Kaiser, Oliver M. Weber, Christoph Katemann, Tatjana Dell, Dmitrij Kravchenko, Can Yueksel, Daniel Kuetting, Claus C. Pieper, Julian A. Luetkens, Alexander Isaak

  • December 20, 2025

Related Content

An efficient pyramid scene parsing network with multi-scale feature fusion for liver segmentation in magnetic resonance imaging

The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort

Graft weight integration in the early allograft dysfunction formula improves the prediction of early graft loss after liver transplantation